ASCO 2024 | Dosing strategy of ponatinib in CP-CML: insights from the OPTIC trial
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, gives an update on the OPTIC trial (NCT02467270) investigating ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML). The study found that a 45 mg dose was most effective, achieving a response rate of over 60%. Reducing the dose after achieving a response effectively mitigated arterial occlusive adverse events (AEs). This dosing strategy was particularly beneficial for patients with T315I mutations. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
